Chao Gao

Showing 1-3 of 3 articles

A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial

Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel M, O'Leary N, Sharif F, Möllmann H, Reiber J, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys P

December 18, 2020 | 10.4244/EIJ-D-20-00772

Valvular heart interventions: advances from 2019 to 2020

Wang R, Gao C, Kawashima H, Modolo R, Rosseel L, Onuma Y, Soliman O, Serruys P, Mylotte D

November 20, 2020 | 10.4244/EIJ-D-20-00096

The year in review: coronary interventions

Gao C, Wang R, Sharif F, Takahashi K, Ono M, Hara H, Tomaniak M, Kawashima H, Modolo R, van Geuns R, Capodanno D, Byrne R, Wijns W, Onuma Y, Serruys P

April 17, 2020 | 10.4244/EIJ-D-19-01124

1

Latest news

EAPCI/ACVC consensus on pVADs, coronary physiology mini focus, a new analysis from the COAPT trial, patient selection for tricuspid interventions and more…

Treatment of secondary mitral regurgitation in patients with heart failure

Marco Metra et al

This Week's JAA's: Principles and Pitfalls in CFT, Brachial access for PCI....

Coronary flow capacity: where to next?

Nils P. Johnson

Joint EAPCI/ACVC expert consensus document on pVADs

EuroIntervention's new impact factor!

STATE OF THE ART

Completeness of Revascularisation in ACS Patients with Multivessel Disease

Valeria Paradies et al.

Valvular disease